                         SEQUENCE LISTING

<110>  INSERM
 
<120>  COMPOSITIONS AND METHODS FOR INDUCING SENESCENCE IN CANCER CELLS

<130>  13121PASSERON

<160>  22    

<170>  PatentIn version 3.3

<210>  1
<211>  1023
<212>  DNA
<213>  Homo sapiens

<400>  1
aaaaagtagt aacgggtccg gcggcagcgc gcgggccggg cgagcgtctc ccggcaaacg     60

cggcgccaca gctgagccga cctccggggc ccgcgccctc ccctccccgg gcaccactag    120

gagcggccag cccgggcctc ggctccgcgc gcggggaaac gagcgcggcg gttaaaaccg    180

ttaccacccc cgagttttga actggttcaa acttggcttc cagcacccgc cccgcccctc    240

ccccgcccgg gaactctgcg gcgccggttc ccgccaagag ccgccggcgc ttcgtcccgc    300

ccttcggccg gttcccgcca cctatcctcc ccgcctcccg tccgcggcgg gctccgggcc    360

cccgcgatgt ctcccggtcc ccgcgtgcct gcacaccgcc ttcctgagag gcgccgtgtg    420

ttcagcgaaa gaacaaagag acggcggcgg cgcttccaca cggccagtgg cgtcccttac    480

agcgaacccc gccgccgccc gcgcgcgcac gcgctgccag tgcccgcccg cccacgagcc    540

ctgagcgcac tctgcgtggg gctggctcgg cgcctccgag cccggcgggc cctgtgattg    600

gacgggcgcc cgcctcgcgt cccgccaatc ggggcggcgc ttgattgggc tgggggggcc    660

aaataaaagc gatggcgatt gggctgccgc gtttggcgct cggtccggtc gcgtccgaca    720

cccggtggga ctcagaaggc agtggagccc cggcggcggc ggcggcggcg cgcgggggcg    780

acgcgcggga acaacgcgag tcggcgcgcg ggacgaaggt aacgcgccgc tgcgggcggc    840

ccggccggcg gggctccggg agtgcgaacc gggcggcggc ggcggcgcca ggacctcccc    900

gccactgctg tgccggtccc gggtatcgcc gagcggggct caccggggcg ccgcgtttgt    960

aggcgtgcgg ggggtggagg gtgaggggag agcccccctc cccggaagga gctgtgagct   1020

tcg                                                                 1023


<210>  2
<211>  10
<212>  DNA
<213>  Artificial

<220>
<223>  EZH2-p52 (1) forward sequence

<400>  2
ggggctcacc                                                            10


<210>  3
<211>  10
<212>  DNA
<213>  Artificial

<220>
<223>  EZH2-p52 (1) reverse sequence

<400>  3
ccccgagtgg                                                            10


<210>  4
<211>  9
<212>  DNA
<213>  Artificial

<220>
<223>  EZH2-p52 (2) forward sequence

<400>  4
ggagagccc                                                              9


<210>  5
<211>  9
<212>  DNA
<213>  Artificial

<220>
<223>  EZH2-p52 (2) reverse sequence

<400>  5
cctctcggg                                                              9


<210>  6
<211>  11
<212>  DNA
<213>  Artificial

<220>
<223>  TFD1 EZH2-p52 (2) forward sequence

<400>  6
atcgggtctc c                                                          11


<210>  7
<211>  12
<212>  DNA
<213>  Artificial

<220>
<223>  TDF1 EZH2-p52 (2) reverse sequence

<400>  7
ggagagcccg at                                                         12


<210>  8
<211>  13
<212>  DNA
<213>  Artificial

<220>
<223>  TFD4 EZH2-p52 (1) forward sequence

<400>  8
atcggggctc acc                                                        13


<210>  9
<211>  13
<212>  DNA
<213>  Artificial

<220>
<223>  TDF4 EZH2-p52 (1) reverse sequence

<400>  9
ggtgagcccc gat                                                        13


<210>  10
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  Peptide P1

<400>  10

Val Gln Arg Lys Arg Arg Lys Ala Leu 
1               5                   


<210>  11
<211>  12
<212>  PRT
<213>  Artificial

<220>
<223>  Cell-penetrating peptide TAT peptide

<400>  11

Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Gln 
1               5                   10          


<210>  12
<211>  25
<212>  RNA
<213>  Artificial

<220>
<223>  siRNA targeting NF-kB2

<400>  12
cccaggucug gaugguauua uugaa                                           25


<210>  13
<211>  25
<212>  RNA
<213>  Artificial

<220>
<223>  siRNA targeting NF-kB2

<400>  13
uucaauaaua ccauccagac cuggg                                           25


<210>  14
<211>  21
<212>  DNA
<213>  Artificial

<220>
<223>  siRNA targeting NF-kB2

<400>  14
aacccaggtc tggatggtat t                                               21


<210>  15
<211>  21
<212>  DNA
<213>  Artificial

<220>
<223>  siRNA targeting NF-kB2

<400>  15
ctggatggta ttattgaata t                                               21


<210>  16
<211>  21
<212>  DNA
<213>  Artificial

<220>
<223>  siRNA targeting NF-kB2

<400>  16
cggcgttgtc aacctcacca a                                               21


<210>  17
<211>  21
<212>  DNA
<213>  Artificial

<220>
<223>  siRNA targeting NF-kB2

<400>  17
aaggacatga ctgcccaatt t                                               21


<210>  18
<211>  25
<212>  RNA
<213>  Artificial

<220>
<223>  siRNA targeting NIK

<400>  18
gccaguccga gagucuugau cagau                                           25


<210>  19
<211>  25
<212>  RNA
<213>  Artificial

<220>
<223>  siRNA targeting NIK

<400>  19
aucugaucaa gacucucgga cuggc                                           25


<210>  20
<211>  21
<212>  DNA
<213>  Artificial

<220>
<223>  siRNA targeting NF-kB2

<400>  20
cacgggcaga ccagtgtcat t                                               21


<210>  21
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  shRNA targeting NF-kB2

<400>  21
ataagatttg aaataggtg                                                  19


<210>  22
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  shRNA targeting NF-kB2

<400>  22
tcagttgcag aaacactgt                                                  19


